Back to Agenda
Part 2 – Strategies in Preparation of Sections 2-5 of Clinical Overview
Session Chair(s)
Diptee A. Gajjar, PhD
Intercontinental Regulatory Strategy Lead
Bristol-Myers Squibb Company, United States
Strategies in Developing Section 2, Overview of Biopharmaceutics and Section 3, Overview of Clinical Pharmacology
Have an account?